IFPMA’s Post

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

✴️ New results have been published estimating the testing requirement to double the diagnostic rates of ≥ F2 MASH over a 5-year period in France, Germany, UK and USA! ➡️ By doubling this rate in all four countries, the number of patients diagnosed will increase from 2.6m to 6.1m between 2022 and 2027. To achieve this, several approaches need to be set up: >> Early intervention is both possible and desirable, to improve outcomes and reduce costs >> More screening calls are needed to strengthen healthcare infrastructure >> Doubling the diagnoses and multiplying the collaborative efforts >> A person-centered approach Echosens supports and advances the liver health management and diagnosis with its gold-standard non-invasive solutions in order to improve the management of silent and under-diagnosed chronic liver diseases. Check the poster now 👉 https://lnkd.in/gPAXqiWe Jeffrey V. Lazarus #FibroScan #LiverHealthMatters #EASL2024

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.

#OpenAccess Stanski et al: Clinical characteristics & outcomes in septic children requiring CRRT 🌍Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease Link: https://ow.ly/XtrZ50TO3Au Editorial: https://ow.ly/CQOA50TO3Aw Society of Critical Care Medicine #pedsICU #survivingsepsis Fig: 90 d mortality for CRRT w & w/o sepsis

At AstraZeneca, our mission #ForKidneyHealth is clear: by 2025, we aim to support the screening of 140 million people at risk of chronic kidney disease (CKD). During #UNGA79, we joined global health experts to highlight the urgent need for earlier detection, diagnosis and better access to treatment and care for CKD. As a critical part of the broader noncommunicable disease (NCD) landscape, CKD’s close connections to cardiovascular and metabolic diseases mean addressing this disease is essential not only for patients, but also for strengthening and decarbonising healthcare systems. Explore the key takeaways from this important discussion, and how we can improve kidney health to transform health systems.